Drug Registration with FDA, EMA, and EAEU: $4.68M NDA Fee and ICH Standards in 2026
A Regulatory Affairs (RA) specialist working exclusively with Russian or Eurasian legislation will eventually ask: how does this work in the rest of the world?
The question has practical weight. Standards developed today by the FDA and EMA become mandatory in the EAEU (Eurasian Economic Union) within three to five years. The eCTD format, pharmacovigilance requirements, clinical trial rules, and biosimilar assessment frameworks all arrived from Western regulatory practice.
This article breaks down how the world’s two largest regulatory systems operate, what market entry costs, and what that comparison means for those working within the EAEU.
How the FDA Works
The U.S. Food and Drug Administration (FDA), established in 1906, is one of the oldest drug safety agencies in the world. Its decisions shape the global pharmaceutical market because the United States remains the largest by sales volume. FDA approval is widely read as a quality signal outside American borders.
The legislative foundation is the Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938, amended many times since.
FDA Centers
The FDA is divided into specialized centers, each responsible for a distinct product category.
CDER (Center for Drug Evaluation and Research) covers chemically synthesized medicinal products. This is where companies file an NDA (New Drug Application) for new molecules and an ANDA (Abbreviated New Drug Application) for generic medicines.
CBER (Center for Biologics Evaluation and Research) evaluates biological medicines, vaccines, blood products, and gene therapies. The relevant filing here is a BLA (Biologics License Application).
CDRH (Center for Devices and Radiological Health) regulates medical devices (MDs) and radiation-emitting equipment through 510(k), De Novo, and PMA (Premarket Approval) pathways.
This division lets each center develop deep domain expertise. The EAEU applies a comparable logic through separate expert organizations, though the final decision rests with a central authority — the Ministry of Health of the Russian Federation at the national level, or the EEC (Eurasian Economic Commission) at the supranational level.
The Economics of U.S. Registration
The FDA’s funding model differs from the Eurasian one in a structural way. Beyond Congressional appropriations, the FDA collects a substantial share of its budget through User Fees — companies pay for the expert labor reviewing their dossiers. This model was created by the PDUFA (Prescription Drug User Fee Act), first passed in 1992. The current version, PDUFA VII, runs from October 2022 through September 2027.
Rates are recalculated each fiscal year (the FDA fiscal year begins October 1). For Fiscal Year 2026 (October 2025 – September 2026):
Table 1: FDA User Fees for Fiscal Year 2026
| Application Type | Standard Fee | Small Business Fee |
|---|---|---|
| NDA/BLA with clinical data | $4,682,003 | — |
| NDA/BLA without clinical data | $2,341,002 | — |
| PMA (Medical Device) | $579,272 | $144,818 |
| 510(k) (Medical Device) | $26,067 | $6,517 |
| De Novo classification request | $173,782 | $43,446 |
| Annual Establishment Registration (MD) | $11,423 | — |
The $4.68 million price tag for a single new drug application puts things in perspective. By comparison, the state duty for registering a medicinal product in Russia runs to a few hundred thousand rubles, while EAEU expertise costs are set through contracts with member-state expert organizations.
Fees continue to climb: PDUFA rates rose approximately 8.6% versus 2025, while medical device establishment fees (MDUFA) increased by 23.1%. Companies can obtain waivers or deferrals for orphan medicines (for rare diseases), first-time small business submissions, or situations where the full fee creates a public health barrier. For large pharmaceutical companies, these fees are a standard budget line.
Timelines and Procedures
A Standard Review for an NDA takes 10 months. Drugs granted Priority Review status receive a decision within 6 months. Priority goes to medicines for serious conditions that offer a material improvement in safety or efficacy over existing therapy.
The FDA also offers four expedited market entry pathways: Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review. Each has its own criteria, but the shared rationale is the same — getting treatments for serious conditions to patients faster when adequate alternatives are unavailable.
The European System: EMA
The European Medicines Agency (EMA) is structured differently from the FDA. Where the FDA is a single regulator for one country, the EMA coordinates 27 national regulatory agencies across the European Union, plus Norway, Iceland, and Liechtenstein (the European Economic Area, EEA). In that sense, the EMA is closer to the EEC model than to the FDA: both are supranational bodies working alongside national regulators.
Registration Procedures
Four routes exist for bringing a medicine to the European market.
The Centralised Procedure (CP) involves one application to the EMA, one evaluation, and one authorization valid across all EU and EEA countries simultaneously. It is mandatory for biotech-derived products, medicines for cancer, HIV, diabetes, neurodegenerative and autoimmune diseases, orphan medicines, and gene and cell therapy products.
The Mutual Recognition Procedure (MRP) starts with authorization in one EU country (the Reference Member State), after which the company requests other countries to recognize that decision.
The Decentralised Procedure (DCP) routes applications to several countries at once, with one acting as lead. It applies to medicinal products not yet authorized in any EU country.
The National Procedure registers a product in a single EU country under its domestic rules.
For EAEU specialists the parallel is straightforward. The Centralised Procedure corresponds to the unified EAEU registration procedure under EEC Council Decision No. 78 of November 3, 2016. MRP and DCP resemble the EAEU mutual recognition procedure, which currently operates on a limited basis.
EMA Fee Reform
On January 1, 2025, Regulation (EU) 2024/568 replaced the fee framework that had been in place since 1995.
The previous three-tier base fee for a Marketing Authorisation Application (MAA) expanded to nine levels tied to the legal basis of the application. Fees are now proportional — their size reflects the actual workload for the EMA and national agencies. Three fee levels cover different types of scientific advice. New charges were added for pre-submissions, date changes, and re-examinations (30% of the original fee).
Exact amounts depend on product category and legal basis, but the order of magnitude runs from hundreds of thousands to several million euros. Industry estimates put the increase for a new active substance at roughly €500,000 compared to the previous system.
Small and medium enterprises (SMEs) retain protections: a 40% discount on MAAs for SMEs, 100% for micro-enterprises, 90% on scientific advice for SMEs, and 100% for SMEs with orphan medicines.
Review Timelines
The Centralised Procedure allows 210 days of active evaluation time, but the actual period from submission to a European Commission decision typically runs 12–14 months once clock stops (time for applicant responses), written clarifications, and oral explanations are included. Accelerated Assessment shortens the evaluation clock to 150 days.
ICH and Global Harmonization
So that pharmaceutical companies operating across multiple markets do not rebuild a dossier from scratch for each regulator, the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) exists.
ICH was founded in 1990 as a dialogue platform between regulators and industry from the United States, Europe, and Japan. Today it includes regulators from many countries; the EEC participates as an observer. The standards developed through ICH define the daily work of RA specialists worldwide.
The eCTD (electronic Common Technical Document) format was created within ICH. The modular registration dossier structure (Modules 1–5), now mandatory in the EAEU, also originated there. Guidelines on stability (ICH Q1), analytical method validation (ICH Q2), impurities (ICH Q3), and pharmaceutical development (ICH Q8–Q12) form the shared technical language of the profession from Tokyo to Moscow.
For an EAEU specialist, understanding the ICH system carries a practical advantage. Many requirements now appearing in Eurasian rules can be found in original ICH guidelines several years before EEC adoption. Nitrosamine control approaches (ICH M7) and product lifecycle requirements (ICH Q12), for instance, are already embedded in FDA and EMA practice while the EAEU is still in the adaptation phase.
Comparing the Three Systems
Table 2: Regulatory Systems Compared — USA, Europe, and EAEU
| Parameter | USA (FDA) | Europe (EMA/NCA) | EAEU (EEC) |
|---|---|---|---|
| New medicinal product review timeline | 10 mo. (Standard), 6 mo. (Priority) | 210 days (active), 12–14 mo. actual | 210–300 working days |
| Application cost | Very high ($4.68M for NDA) | High (category-dependent) | Low (state duties + expertise) |
| Dossier language | English | English (+ label translations into EU languages) | Russian |
| Dossier format | eCTD (mandatory) | eCTD (mandatory for CP) | eCTD (mandatory from 2025) |
| Expedited pathways | Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review | Accelerated Assessment, Conditional MA, PRIME | Accelerated procedure (select categories) |
| Post-authorization monitoring | Strict; REMS where required | Annual safety reports, PSUR (Periodic Safety Update Report) | Pharmacovigilance (PV) per EAEU rules |
| Countries covered | 1 (USA) | 30 (EU + EEA) | 5 (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan) |
Professional Organizations
Two professional bodies are worth knowing in the RA field.
RAPS (Regulatory Affairs Professionals Society), the largest such organization in the world, was founded in 1976 and is headquartered near Washington, D.C. Annual membership runs from $55 to $245 depending on category. RAPS offers the RAC (Regulatory Affairs Certification), the only post-academic professional credential in the field recognized at the international level. For a specialist planning a career with multinational companies, RAC is a visible asset in a CV.
TOPRA (The Organisation for Professionals in Regulatory Affairs) is oriented toward the European regulatory community, founded in 1991 and based in the United Kingdom. Annual membership is approximately £200. TOPRA provides access to deep European expertise, professional development programs, and Chartered Scientist status for qualified members.
Both organizations hold conferences, publish research, and offer educational resources. For EAEU-based specialists working on international projects, membership in either opens access to a professional network and current information that is difficult to find through open sources.
What This Comparison Means in Practice
Standards flow downward. What is mandatory in FDA and EMA today will appear in EEC requirements within a few years. Following ICH publications and FDA/EMA draft guidelines is not theoretical interest — it is preparation for norms that will soon be binding.
The dossier structure is already unified. eCTD and the modular CTD format are in use across FDA, EMA, and the EAEU. A company that builds its registration dossier to CTD/eCTD standards from the start can adapt it for other markets with relatively modest effort.
The cost gap is substantial. EAEU registration costs orders of magnitude less than in the United States or Europe. For Russian and Eurasian manufacturers, this is a competitive advantage on their home market. For foreign companies entering the EAEU, lower fees are offset by the language barrier and the need to navigate procedures specific to the region.
Expedited pathways exist in all three systems but differ in maturity. The FDA offers four well-defined accelerated routes with clear criteria. The EMA has Accelerated Assessment and the PRIME program. The EAEU provides for accelerated expertise in certain product categories, but the mechanism is less developed.
Building a Career in International RA
Study the ICH guideline structure. Start with ICH Q1 (stability), Q2 (analytical validation), and Q8–Q12 (pharmaceutical development and lifecycle). These are the foundational documents underlying the requirements of all three systems.
Subscribe to FDA and EMA updates. The FDA publishes draft guidelines at fda.gov; the EMA publishes at ema.europa.eu. Reading these documents gives a picture of where global regulation is heading.
Assess the value of international certification. If your career or your company’s work involves international markets, consider RAPS or TOPRA membership and preparation for the RAC credential.
Compare procedures actively. When preparing an EAEU dossier, check how equivalent requirements are framed in FDA and EMA guidelines. The original ICH formulation often clarifies ambiguous passages in Eurasian rules.
Prepare dossiers with international standards in mind from the outset. Even if you currently work exclusively in the EAEU, building a dossier according to CTD/eCTD principles from day one will save time and resources when the company eventually moves into other markets.
Sources: EEC Council Decision No. 78 of November 3, 2016 on the Rules for Registration and Evaluation of Medicinal Products; Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301–399i); Prescription Drug User Fee Amendments of 2022 (PDUFA VII); Federal Register, July 30, 2025 — Prescription Drug User Fee Rates for Fiscal Year 2026; Federal Register, July 30, 2025 — Medical Device User Fee Rates for Fiscal Year 2026; Regulation (EC) No 726/2004 of the European Parliament and of the Council (centralised procedure); Regulation (EU) 2024/568 on fees and charges payable to the EMA.
Other articles on Regulatory Affairs →